Limei Ai
Impact in
-
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- Multiple Myeloma Research and Treatments
Papers in
-
- CRISPR and Genetic Engineering 3
- Viral Infectious Diseases and Gene Expression in Insects 2
- Histone Deacetylase Inhibitors Research 2
- Microbial Metabolic Engineering and Bioproduction 2
-
- Lymphoma Diagnosis and Treatment 2
- Co-authors
- Shanshan Yu (3 shared papers)Wei Wei (1 shared paper)Wei Sun (1 shared paper)Yang Yu (1 shared paper)Ning Zhang (2 shared papers)Jing Pan (2 shared papers)Jing Pan (1 shared paper)Shanshan Yu (1 shared paper)
- Journals
- Tumor Biology (2 papers)Biology Direct (1 paper)Xenobiotica (1 paper)Current Microbiology (1 paper)Frontiers in Immunology (1 paper)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Limei Ai
24 papers receiving 320 citations
Peers
Comparison fields: 5 of 66
- Cancer Research 70
- Hematology 48
- Pharmacology 30
- Molecular Biology 190
- Genetics 27
Countries citing papers authored by Limei Ai
This map shows the geographic impact of Limei Ai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Limei Ai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Limei Ai more than expected).
Fields of papers citing papers by Limei Ai
This network shows the impact of papers produced by Limei Ai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Limei Ai. The network helps show where Limei Ai may publish in the future.
Co-authors
The 25 scholars most cited alongside Limei Ai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 75 | |
| 2 | 2017 | 55 | |
| 3 | 2013 | 54 | |
| 4 | 2017 | 27 | |
| 5 | 2020 | 25 | |
| 6 | 2015 | 14 | |
| 7 | 2025 | 13 | |
| 8 | 2018 | 10 | |
| 9 | 2013 | 8 | |
| 10 | 2019 | 8 | |
| 11 | 2024 | 7 | |
| 12 | 2015 | 6 | |
| 13 | 2019 | 5 | |
| 14 | 2022 | 4 | |
| 15 | 2022 | 3 | |
| 16 | 2024 | 2 | |
| 17 | [Survival and prognosis of patients with polycythemia vera: a study of 816 patients in a single Chinese center]. | 2015 | 2 |
| 18 | 2019 | 2 | |
| 19 | 2023 | 1 | |
| 20 | [Inhibition of TLR4 represses proliferation and invasion ability of Raji lymphoma cells]. | 2018 | 1 |
About Limei Ai
Limei Ai is a scholar working on Molecular Biology, Pathology and Forensic Medicine, Hematology, Cancer Research and Pharmacology, having authored 25 papers that have together received 326 indexed citations. Recurring topics across this work include CRISPR and Genetic Engineering (3 papers), Ferroptosis and cancer prognosis (2 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers), CAR-T cell therapy research (2 papers), Viral Infectious Diseases and Gene Expression in Insects (2 papers), Histone Deacetylase Inhibitors Research (2 papers), Lymphoma Diagnosis and Treatment (2 papers) and Microbial Metabolic Engineering and Bioproduction (2 papers). The work is most often cited by research in Cancer Research (70 citations), Hematology (48 citations), Pharmacology (30 citations), Molecular Biology (190 citations) and Genetics (27 citations). Limei Ai has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Shanshan Yu, Wei Wei, Wei Sun, Yang Yu, Ning Zhang, Jing Pan, Jing Pan, Shanshan Yu, Wei Wei and Yuanyuan Sun. Their work appears in journals such as Tumor Biology, Biology Direct, Xenobiotica, Current Microbiology and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.